Positron Sees Cardiac PET as the Future of Nuclear Cardiology

INDIANAPOLIS--(Business Wire)--
Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused
on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET
imaging will be greatly accelerated with the recent changes in reimbursement
from the Centers for Medicare & Medicaid Services (CMS) set for 2010.

The Medicare Physician Fee Schedule outlines the payment rates for medical
services paid to private physicians in the outpatient office setting. This
document states that Myocardial PET perfusion imaging was increased 20% to
$1,432.87 per study. The Schedule also states that Cardiovascular SPECT
reimbursement for outpatient cardiology practices billing under CPT codes has
been reduced by 36% representing a differential of greater than $1,000 between
tests.

Joseph Oliverio, Chief Technology Officer of Positron Corporation stated, "An
elevated concern over existing Molybdenum shortages, patient radiation exposure,
and increased PET reimbursement combined with cuts for SPECT imaging has
resulted in industry experts designating Cardiac PET as the immediate future of
Nuclear Cardiology." Mr. Oliverio also went on to state, "Positron`s Attrius,
which is optimized for Cardiac PET imaging, is the ideal solution for
Cardiologists looking to add new technology to their practice. Positron`s PET
scanner, with its robust software package, will help physicians provide a more
accurate diagnosis for patients, a reduction of unnecessary downstream
procedures and a very attractive economic alternative to SPECT. Additionally,
there are new PET myocardial perfusion agents in clinical phase III trials and
more than three other Cardiovascular PET specific radiopharmaceuticals in
clinical phase I & II, which will quickly drive demand for Positron`s Attrius
Cardiac PET system, the only new PET only device available today."

Source: Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician
Fee Schedule.

About Positron: Positron is a molecular imaging company focused on Nuclear
Cardiology. Positron utilizes its proprietary product line to provide unique
solutions to the Nuclear Medicine community ranging from imaging to
radiopharmaceutical distribution. Positron products include: the Attrius, a PET
imaging device; the Pulse, a SPECT imaging device; the Nuclear Pharm-Assist, an
automated radiopharmaceutical distribution device; and the Tech-Assist, a
radiopharmaceutical injection shield. More information about Positron is
available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not guarantees of
future performance and may involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.

Positron Corporation
Joseph Oliverio, (317)576-0183

Copyright Business Wire 2009